Article Figures & Data
Figures
- FIGURE 1.
(A and B) Box plots of SUV in blood at 40–45 min after injection for 68Ga-DOTATOC (A) and 68Ga-DOTATATE (B) for high and low Ki values. One tumor per patient is included in plots. Boxes are median and interquartile range, and whiskers are full range of data. Significant differences (P < 0.05) were found in SUVblood between high and low Ki for 68Ga-DOTATOC, however, not for 68Ga-DOTATATE (P > 0.05). (C and D) Relation between Ki and SUV in blood for 68Ga-DOTATOC (C) and 68Ga-DOTATATE (D). Solid line represents exponential fit (y = a/x) for visual illustration.
- FIGURE 2.
Correlation between Ki and TBR for 68Ga-DOTATOC (A) and 68Ga-DOTATATE (B) and between Ki and SUV in tumors for 68Ga-DOTATOC (C) and 68Ga-DOTATATE (D). Solid lines represent linear regression fits (A and B) and fits to hyperbolic line (C and D), and dashed lines are 95% confidence band of these fits.
- FIGURE 3.
Comparison of Ki, SUVtumor, and TBR between 68Ga-DOTATOC and 68Ga-DOTATATE. Significant difference was found between 68Ga-DOTATOC and 68Ga-DOTATATE for TBR (P = 0.019, Wilcoxon matched-pairs test) but not for Ki or SUVtumor (P = 0.083 and 0.413, respectively).
Tables
Sex Age (y) NET type Tracer Peptide (μg) Ki-67 index Previous surgery History and previous therapy Metastases Ongoing therapy F 67 pNET/NEC (glucagonoma) TOC/TATE 23/23 3% — SSA, streptozotocin-fluorouracil, PRRT, transformation to NEC and carboplatine-etopside Liver — F 63 SI NET TOC/TATE 17/29 1% Primary tumor Liver trpl 1999 because of cyst disease Liver, mesenteric lgl — M 67 SI NET TOC/TATE 18/30 1% Primary tumor — Liver, mesenteric lgl SSA M 50 SI NET TOC/TATE 20/33 18% Primary tumor mesenteric lgll — Liver, mesenteric lgl, retroperitoneal lgll SSA M 64 pNEC TOC/TATE 26/25 30% — Avastin, temozolomide Liver — F 73 pNET TOC/TATE 22/22 3% — Streptozotocin-fluorouracil Liver, abdominal lgll SSA M 57 SI NET TOC 25 3% — SSA Abdominal lgll, mesenteric lgl SSA M 53 pNET (malignant insulinoma) TOC 18 3% Primary tumor Streptozotocin-fluorouracil, Sirtex Liver, mesenteric lgl Everolimus F 72 pNET (MEN-1, gastrin-producing) TOC 15 No biopsy — — Retroperitoneal lgll — M 51 pNET TOC 22 3% Primary tumor — Retroperitoneal lgll — M 74 SI NET TOC 23 1% — — Mesenteric lgll — F 67 pNET TOC 25 2% — Streptozotocin-fluorouracil Liver — M 50 SI NET TOC 47 4% — — Liver, mesenteric lgl, peritoneal carcinomatosis SSA F* 52 SI NET TOC 25 5% — — Liver, mesenteric thoracic neck lgll, bone, breast, ovary SSA F 69 SI NET TOC 27 9% — — Liver, bone SSA F 47 SI NET TOC 41 9% — — Liver, mesenteric lgl, abdominal and retroperitoneal lgll SSA M 72 Rectal NET TATE 13 30% — — Liver, pararectal lgll — F 69 SI NET TATE 22 12% — — Liver, peritoneal carcinomatosis SSA M 67 pNET TATE 8 17% — — Liver, abdominal lgll, bone SSA M 75 Rectal NET TATE 14 10% — — Liver, abdominal lgll, peritoneal carcinomatosis — F* 53 SI NET TATE 16 5% Primary tumor — Liver, abdominal lgll, bone, breast, lung SSA F 58 Duodenal NET (gastrinoma) TATE 22 3% Primary tumor liver resection, RF — Liver SSA F 75 Atypical lung NET TATE 39 6% SSA ↵* Same patient.
pNET = pancreatic NET; NEC = neuroendocrine carcinoma; TOC = 68Ga-DOTATOC; TATE = 68Ga-DOTATATE; SSA = long acting somatostatin analog; PRRT = peptide receptor radionuclide therapy; SI = small intestine; trpl = transplantation; lgl = single lymph node; lgll = multiple lymph nodes; Sirtex = transarterial liver embolization with 90Y-spheres; MEN-1 = multiple endocrine neoplasia type 1; RF = radiofrequency ablation.
Reconstruction setting Discovery ST Discovery IQ Discovery MI Reconstruction algorithm OSEM OSEM with PSF modeling ToF OSEM with PSF modeling Iterations/subsets 2/28 4/12 3/16 Postprocessing filter (mm) 5 4 5 Matrix size 128 × 128 256 × 256 256 × 256 Pixel size (mm) 3.91 × 3.91 × 3.27 1.95 × 1.95 × 3.26 1.95 × 1.95 × 2.79 OSEM = ordered-subset expectation maximization; PSF = point-spread function; ToF = time of flight.
Supplemental Data
Files in this Data Supplement:
